Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 9/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17863662 | 0.95 | HCRTR1 (0.50) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL16512784 | 0.95 | HCRTR1 (0.50) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL16486932 | 0.95 | HCRTR1 (0.50) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL4020552 | 0.91 | HCRTR1 (0.56) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL4024302 | 0.91 | HCRTR1 (0.56) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL4020548 | 0.91 | HCRTR1 (0.56) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL16486704 | 0.80 | HCRTR1 (0.49) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL16512738 | 0.80 | HCRTR1 (0.49) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL16486620 | 0.80 | HCRTR1 (0.49) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES | |
| SCHEMBL20747142 | 0.80 | HCRTR1 (0.49) | HCRTR1TAS1R3TAS1R1TAS1R2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932396-B2 | 2-pyridinylcycloalkylbenzamide derivatives and their use as fungicides | BAYER CROPSCIENCE AG (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20090076096-A1 | 2-Pyridinylcycloalkylbenzamide derivatives and their use as fungicides | BAYER CROPSCIENCE AG (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1885698-A1 | 2-PYRIDINYLCYCLOALKYLBENZAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | Bayer CropScience S.A. (FR) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006122952-A1 | 2-PYRIDINYLCYCLOALKYLBENZAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076096-A1 | 2-Pyridinylcycloalkylbenzamide derivatives and their use as fungicides | CYP1A2, CYP4B1, CYP4F2 | HCRTR1 3971/4885TAS1R3 1877/4885TAS1R1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.